Halozyme Therapeutics Inc
Research Halozyme Therapeutics Inc (HALO) on Bullrun: valuation model: 14.3% overvalued, market cap USD 9.15B, P/E 27.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHALO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal14.3% overvalued
- Market capUSD 9.15B
- P/E27.8
- Financial periodFY2025
- RevenueUSD 1.40B
- Revenue growth37.6%
- Net incomeUSD 316.89M
- Free cash flowUSD 644.59M
- Gross margin83.6%
Valuation Snapshot
Bullrun's latest valuation model marks Halozyme Therapeutics Inc as 14.3% overvalued; latest market cap is USD 9.15B; P/E is 27.8.
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Frequently asked questions
Is Halozyme Therapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Halozyme Therapeutics Inc as 14.3% overvalued.
What is Halozyme Therapeutics Inc's market cap?
Halozyme Therapeutics Inc's market capitalization is USD 9.15B.
What is Halozyme Therapeutics Inc's P/E ratio?
Halozyme Therapeutics Inc's price-to-earnings (P/E) ratio is 27.8.
What does Halozyme Therapeutics Inc do?
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.